Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomised Controlled Trial to Assess the Immunogenicity, Safety and Reactogenicity of Standard Dose Versus Fractional Doses of COVID-19 Vaccine (Pfizer-BioNTech) Given as a Booster Dose After Priming With Sinopharm, AstraZeneca or Sputnik in Healthy Adults in Mongolia

NCT05265065 is registered in ClinicalTrials.gov with Murdoch Childrens Research Institute as lead sponsor.

NCT NCT05265065
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05265065 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomised Controlled Trial to Assess the Immunogenicity, Safety and Reactogenicity of Standard Dose Versus Fractional Doses of COVID-19 Vaccine (Pfizer-BioNTech) Given as a Booster Dose After Priming With Sinopharm, AstraZeneca or Sputnik in Healthy Adults in Mongolia
Lead sponsor
Murdoch Childrens Research Institute
Phase
Phase 3
Overall status
Completed
Start date
May 27, 2022
Completion date
November 6, 2024
Enrollment
601 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

covid-19